Sage Therapeutics Newsroom

Sage Therapeutics Analyst Ratings

BenzingaJul 2 13:32 ET

SAGE Therapeutics: A Balanced Hold Rating Amidst Promising Zurzuvae Launch and Clinical Pipeline Prospects

TipRanksJul 2 11:49 ET

Sage Therapeutics Analyst Ratings

BenzingaJun 28 05:48 ET

Sage Therapeutics Analyst Ratings

BenzingaJun 20 09:17 ET

JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $23

BenzingaJun 20 09:16 ET

Sage Therapeutics Analyst Ratings

BenzingaJun 12 07:00 ET

HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $25 Price Target

BenzingaJun 12 06:59 ET

Sage Therapeutics Analyst Ratings

BenzingaJun 11 08:40 ET

Sell Rating on SAGE Therapeutics Amid Concerns Over Zurzuvae's Market Adoption and Safety Profile

TipRanksMay 30 23:00 ET

Baird Initiates Sage Therapeutics With Neutral Rating, $15 Price Target

MT NewswiresMay 29 06:23 ET

Sage Therapeutics Analyst Ratings

BenzingaMay 29 05:11 ET

Sell Rating on SAGE Therapeutics Amidst High Risk and Uncertain Pipeline Success

TipRanksMay 28 17:56 ET

Sage Therapeutics Analyst Ratings

BenzingaMay 1 11:24 ET

JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $28

BenzingaMay 1 11:24 ET

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Gilead Sciences (GILD) and SAGE Therapeutics (SAGE)

TipRanksApr 30 03:05 ET

Sage Therapeutics Analyst Ratings

BenzingaApr 26 12:03 ET

SAGE Therapeutics: Hold Rating Amidst Zurzuvae Success and Dalzanemdor Setbacks

TipRanksApr 26 08:41 ET

Balancing Opportunity and Risk: Hold Rating on SAGE Therapeutics Amidst High-Stakes Catalysts and Financial Reassessment

TipRanksApr 26 08:12 ET

SAGE Therapeutics (SAGE) Receives a Hold From RBC Capital

TipRanksApr 26 06:37 ET

Sage Therapeutics Analyst Ratings

BenzingaApr 26 05:31 ET